OMNIPAQUE 350mg I/ml Price

Overview

Welcome to Dwaey, specifically on OMNIPAQUE 350mg I/ml Injection/Solution for page.
This medicine contains an important and useful components, as it consists of Iohexol.
OMNIPAQUE 350mg I/ml is available in the market in concentration 755mg/ml and in the form of Injection/Solution for.

GE HEALTHCARE AS is the producer of OMNIPAQUE 350mg I/ml and it is imported from NORWAY, The most popular alternatives of OMNIPAQUE 350mg I/ml are listed downward .

Mode Of Action

Allows for radiographic visualization through the opacification of vessels and anatomical structures in the path of flow of the contrast media.

Indication

• Radiographic contrast medium for diagnostic procedures

Precaution

Asthma or a history of allergies (risk of anaphylactoid reactions is increased); compromised blood-brain barrier (severe neurotoxicity after intrathecal use); epilepsy and brain tumour (higher risk of convulsions); severe hepatic or renal impairment, diabetics with renal impairment, dehydration and others who may be at increased risk of renal failure; multiple myeloma (dehydration from use may cause precipitation of protein in the renal tubules, leading to anuria and fatal renal failure); severe hypertension; advanced cardiac disease; phaeochromocytoma; sickle-cell disease; hyperthyroidism; debilitated, severely ill, very old, or very young patients; occlusive vascular disease. Special care to ensure that 140 and 350 mg iodine/ml solutions are not given intrathecally. Adequate resuscitative facilities should be available when radiographic procedures are undertaken, and patients should be kept under observation for a suitable period after the procedure. Lactation: Not known; not recommended

Side Effects

• Flushing or a sensation of heat; pain
• extravasation
• thrombophlebitis at the inj site; nausea
• vomiting
• headache
• and dizziness; urticaria
• pruritus
• pallor
• sweating
• metallic taste
• weakness
• coughing
• rhinitis
• sneezing
• lachrymation
• visual disturbances; hypotension
• tachycardia
• bradycardia
• transient ECG abnormalities
• haemodynamic disturbances; dyspnoea
• bronchospasm
• angioedema
• severe urticaria; convulsions
• paraesthesia
• paralysis; acute renal failure; thromboembolism
• disseminated intravascular coagulation
• thrombocytopenia; hyperthyroidism
• thyroid storm thyrotoxicosis. Potentially Fatal: Profound hypotension
• pulmonary oedema
• respiratory arrest
• ventricular fibrillation
• circulatory failure
• cardiac arrest
• coma.

Contra indication

Procedure-specific. Intrathecal: Myelography in significant local or systemic infection where bacteremia is likely; concurrent use with corticosteroids; repeat myelography in the event of technical failure (risk of overdosage). Hysterosalpingography: During menstrual period or when menstrual flow in imminent; presence of infection; pregnancy, 6 mth after termination of pregnancy or 30 days after conization or curettage.

Pregnancy and lactation

Pregnancy category: B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.